AstraZeneca Didn't Deserve Seroquel Extension, DC Circ. Says
AstraZeneca had claimed it should have gotten three more years of Seroquel exclusivity after it submitted new clinical data in 2008 on possible side effects alongside two supplemental new drug applications for pediatric use of the drug.
Although the FDA approved the sNDAs and gave AstraZeneca three more years...
Already a subscriber? Click here to login